Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
5Customers
3Debt Items
2Related Chains
Source-Backed Evidence Depth
Elicio Therapeutics, Inc. (ELTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
1Distinct source URLs
9High confidence
0.817Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Elicio Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
GKCC
GKCC
92%
In June 2025, the Company closed the June 2025 Promissory Note Financing with GKCC, pursuant to which the Company issued the
B-RILEY-SECURITIES-INC
B-RILEY-SECURITIES-INC
90%
In March 2026, the Company entered into the At Market Issuance Sales Agreement with B. Riley Securities, Inc. ("B. Riley Securities"), Jones, and Ladenburg Thalmann & Co. Inc. ("Ladenburg Thalmann"),…
LADENBURG-THALMANN-CO-INC
LADENBURG-THALMANN-CO-INC
90%
In March 2026, the Company entered into the At Market Issuance Sales Agreement with B. Riley Securities, Inc. ("B. Riley Securities"), Jones, and Ladenburg Thalmann & Co. Inc. ("Ladenburg Thalmann"),…
MASSACHUSETTS-INSTITUTE-OF-TECHNOLOGY
MASSACHUSETTS-INSTITUTE-OF-TECHNOLOGY
90%
In January 2016, Former Elicio entered into a license agreement to license certain intellectual property rights from the Massachusetts Institute of Technology ("MIT"), which agreement has been amende…
Elicio Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
GKCC
GKCC
92%
The Company issued 3,500,573 shares of its common stock to GKCC in exchange for the principal balance of $ 20.0 million plus $ 0.3 million in accrued interest, in satisfaction in full of the Converti…
Reciprocal relationship from ANGI graph: Reciprocal relationship from ELTX graph: Reciprocal relationship from ANGI graph: Reciprocal relationship from ELTX graph: Reciprocal relationship from ANGI g…
ANGION-BIOMEDICA-CORP
ANGION-BIOMEDICA-CORP
62%
n eliminated. These interim financial statements are unaudited and reflect all normal recurring adjustments that are, in the opinion of management, necessary for the fair statement of such interim fi…
K-EMERGING-GROWTH-COMPANY
K-EMERGING-GROWTH-COMPANY
62%
he licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; ▪ our need and ability to hire additional personnel, including management, clinical de…
NASDAQ-STOCK-MARKET-LLC
NASDAQ-STOCK-MARKET-LLC
62%
n eliminated. These interim financial statements are unaudited and reflect all normal recurring adjustments that are, in the opinion of management, necessary for the fair statement of such interim fi…
Elicio Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ELTX-DEBT
Debt stack $9.5M
90%
Market cache reports total debt of $9.5M.
ELTX-DEBT-9271
Warrants outstanding: 1261830
90%
xbrl warrant detail from xbrl 2025-12-31.
ELTX-DEBT-9272
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
Elicio Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Elicio Therapeutics, Inc..
Elicio Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
ELTX-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 49 tracked holders.
Elicio Therapeutics, Inc. Extended Supply Chain Network
